Literature DB >> 23716052

Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.

Hee Ji Lee1, Phillip J Bergen, Jurgen B Bulitta, Brian Tsuji, Alan Forrest, Roger L Nation, Jian Li.   

Abstract

Combination therapy may be required for multidrug-resistant (MDR) Acinetobacter baumannii. This study systematically investigated bacterial killing and emergence of colistin resistance with colistin and rifampin combinations against MDR A. baumannii. Studies were conducted over 72 h in an in vitro pharmacokinetic (PK)/pharmacodynamic (PD) model at inocula of ~10(6) and ~10(8) CFU/ml using two MDR clinical isolates of A. baumannii, FADDI-AB030 (colistin susceptible) and FADDI-AB156 (colistin resistant). Three combination regimens achieving clinically relevant concentrations (constant colistin concentration of 0.5, 2, or 5 mg/liter and a rifampin maximum concentration [C(max)] of 5 mg/liter every 24 hours; half-life, 3 h) were investigated. Microbiological response was measured by serial bacterial counts. Population analysis profiles assessed emergence of colistin resistance. Against both isolates, combinations resulted in substantially greater killing at the low inoculum; combinations containing 2 and 5 mg/liter colistin increased killing at the high inoculum. Combinations were additive or synergistic at 6, 24, 48, and 72 h with all colistin concentrations against FADDI-AB030 and FADDI-AB156 in, respectively, 8 and 11 of 12 cases (i.e., all 3 combinations) at the 10(6)-CFU/ml inoculum and 8 and 7 of 8 cases with the 2- and 5-mg/liter colistin regimens at the 10(8)-CFU/ml inoculum. For FADDI-AB156, killing by the combination was ~2.5 to 7.5 and ~2.5 to 5 log(10) CFU/ml greater at the low inoculum (all colistin concentrations) and high inoculum (2 and 5 mg/liter colistin), respectively. Emergence of colistin-resistant subpopulations was completely suppressed in the colistin-susceptible isolate with all combinations at both inocula. Our study provides important information for optimizing colistin-rifampin combinations against colistin-susceptible and -resistant MDR A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23716052      PMCID: PMC3719722          DOI: 10.1128/AAC.00703-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

Review 1.  Peptide antibiotics.

Authors:  R E Hancock; D S Chapple
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Timothy C Smeaton; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 3.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Authors:  Matthew E Falagas; Sofia K Kasiakou
Journal:  Clin Infect Dis       Date:  2005-03-22       Impact factor: 9.079

4.  In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii.

Authors:  G M Hogg; J G Barr; C H Webb
Journal:  J Antimicrob Chemother       Date:  1998-04       Impact factor: 5.790

5.  Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

Authors:  Sofia K Kasiakou; Argyris Michalopoulos; Elpidoforos S Soteriades; George Samonis; George J Sermaides; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Rifampin: mechanisms of action and resistance.

Authors:  W Wehrli
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

7.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

8.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

9.  Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii.

Authors:  E J Giamarellos-Bourboulis; E Xirouchaki; H Giamarellou
Journal:  Diagn Microbiol Infect Dis       Date:  2001-07       Impact factor: 2.803

10.  Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.

Authors:  Abelardo Montero; Javier Ariza; Xavier Corbella; Alejandro Doménech; Carmen Cabellos; Josefina Ayats; Fe Tubau; Carmen Borraz; Francesc Gudiol
Journal:  J Antimicrob Chemother       Date:  2004-11-16       Impact factor: 5.790

View more
  34 in total

1.  Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.

Authors:  Qi Tony Zhou; Thomas Gengenbach; John A Denman; Heidi H Yu; Jian Li; Hak Kim Chan
Journal:  AAPS J       Date:  2013-10-16       Impact factor: 4.009

2.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

Review 3.  Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Authors:  Phillip J Bergen; Zackery P Bulman; Sarith Saju; Juergen B Bulitta; Cornelia Landersdorfer; Alan Forrest; Jian Li; Roger L Nation; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2015-01       Impact factor: 4.705

4.  Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.

Authors:  Bingxuan Cai; Yiying Cai; Yi Xin Liew; Nathalie Grace Chua; Jocelyn Qi-Min Teo; Tze-Peng Lim; Asok Kurup; Pui Lai Rachel Ee; Thuan Tong Tan; Winnie Lee; Andrea Lay-Hoon Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

5.  Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers.

Authors:  Shu J Lam; Neil M O'Brien-Simpson; Namfon Pantarat; Adrian Sulistio; Edgar H H Wong; Yu-Yen Chen; Jason C Lenzo; James A Holden; Anton Blencowe; Eric C Reynolds; Greg G Qiao
Journal:  Nat Microbiol       Date:  2016-09-12       Impact factor: 17.745

6.  Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.

Authors:  John K Diep; David M Jacobs; Rajnikant Sharma; Jenna Covelli; Dana R Bowers; Thomas A Russo; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 7.  Synergistic combinations of polymyxins.

Authors:  Justin R Lenhard; Roger L Nation; Brian T Tsuji
Journal:  Int J Antimicrob Agents       Date:  2016-10-24       Impact factor: 5.283

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Authors:  Brian T Tsuji; Cornelia B Landersdorfer; Justin R Lenhard; Soon-Ee Cheah; Visanu Thamlikitkul; Gauri G Rao; Patricia N Holden; Alan Forrest; Jürgen B Bulitta; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae.

Authors:  Su Mon Aye; Irene Galani; Heidi Yu; Jiping Wang; Ke Chen; Hasini Wickremasinghe; Ilias Karaiskos; Phillip J Bergen; Jinxin Zhao; Tony Velkov; Helen Giamarellou; Yu-Wei Lin; Brian T Tsuji; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.